Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REN001 versus placebo in primary mitochondrial myopathy
NL-OMON51665Phase 2Active, not recruiting
- Sponsor
- Reneo Pharmaceuticals
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary mitochondrial myopathies (PMM) comparing REN001 with Placebo (2 arms). Primary endpoint: Change from baseline in distance walked during the 12-minute walk test. Started May 2022; status: active, not recruiting.
02
Drugs
mavodelpar
03
Conditions
primary mitochondrial myopathies (PMM)
Beyond the preview
Go deeper on NL-OMON51665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51665.